TABLE 5.

Selected laboratory assay values over time from comparator-controlled phase III clinical trials of linezolid^a

Assay (units)	Baseline	Treatment days 1-7	Posttreatment days:
			1-7	15-21
ALT (U/liter)
Linezolid	33.0 ± 59.9	38.4 ± 115.2	37.7 ± 60.7	28.4 ± 31.8
Comparators	34.4 ± 58.8	37.0 ± 74.4	35.1 ± 92.2	27.2 ± 29.4
AST (U/liter)
Linezolid	33.3 ± 66.4	36.9 ± 180.8	32.2 ± 76.7	25.5 ± 21.2
Comparators	32.4 ± 45.2	34.4 ± 121.6	34.5 ± 152.2	25.7 ± 19.4
Amylase (U/liter)
Linezolid	50.0 ± 36.7	54.9 ± 45.7	60.4 ± 31.8	58.5 ± 30.0
Comparators	52.9 ± 55.7	56.4 ± 39.5	61.5 ± 34.1	59.1 ± 32.9
Lipase (U/liter)
Linezolid	83.6 ± 85.1	96.5 ± 103.4	99.6 ± 99.4	88.6 ± 70.1
Comparators	90.5 ± 134.0	105.0 ± 120.9	105.6 ± 120.3	88.3 ± 73.5
Hemoglobin (g/dl)
Linezolid	12.93 ± 2.16	12.73 ± 2.12	13.06 ± 1.89	12.96 ± 1.94
Comparators	12.89 ± 2.26	12.75 ± 2.11	13.05 ± 2.03	13.18 ± 1.94
Neutrophils (103/mm3)
Linezolid	7.86 ± 5.30	5.85 ± 4.11	4.93 ± 3.07	4.89 ± 3.04
Comparators	7.83 ± 5.04	5.77 ± 3.59	5.20 ± 3.68	4.71 ± 2.72
Platelets (103/mm3)
Linezolid	260 ± 102	290 ± 116	284 ± 121	292 ± 99
Comparators	264 ± 111	292 ± 116	312 ± 121	261 ± 94
WBCs (103/mm3)
Linezolid	10.75 ± 6.07	8.42 ± 4.45	7.54 ± 3.61	7.63 ± 3.38
Comparators	10.54 ± 5.78	8.44 ± 4.05	7.87 ± 4.03	7.47 ± 3.19

^aThe values are means ± SDs.